CURRENT INDICATORS OF ANTIFUNGAL RESISTANCE OF CANDIDA SPECIES

Ziyokhujaeva Nozima Baxtiyor qizi

Authors

Ziyokhujaeva Nozima Baxtiyor Qizi The fourth-year student of KIMYO INTERNATIONAL UNIVERSITY IN TASHKENT In Beauty Aesthetic faculty.

Keywords:

urogenital candidiasis, Candida species, antifungal drugs, itraconazole, fluconazole, miconazole, resistance.

Abstract

The article presents the results of the evaluation of modern sensitivity indicators to antifungal preparations in 1052 strains of Candida species isolated from patients with urogenital candidiasis in the period from 2010 to 2015. Pathogen culture identified was examined to determine the sensitivity to amphotericin В, 5-fluorocytosine, fluconazole, itraconazole, ketoconazole, and miconazole. At present, along with a predominance of Candida albicans, the etiological range of causative agents of urogenital candidiasis is characterized by an increasing proportion of non-albicans species (Candida glabrata, Candida krusei, Candida parapsilosis). Heterogeneous specific structure of the disease and increase in resistance rates of Candida to commonly used azole antifungals (fluconazole, itraconazole, miconazole) necessitate permanent monitoring of the sensitivity of infectious agents to antifungals and optimizing treatment regimens based on these indicators.

References

Prilepskaya V.N., Bayramova G.R. Vulvovaginal candidiasis. Clinic, dia-Gnostics, principles of therapy. M., 2010.

Ivanova I.I., Stepanyan A.V., Jobava E.M.,Dobrokhotova Yu.E. Application experience Lomexine (fenticonazole) in the treatment of can-didosis vulvovaginitis. Gynecology.2012;14:72–5.

Corsello S.A., Spinillo G., Osnengo C., Penna S.,Guaschino A., Beltrame N., Festa A. An epidemiological survey of vulvovaginal candidiasis in Italy. Eur. J. Obstet. Gynecol.Reprod. Biol. 2003;110:66–72.

Rakhmatulina M.R., Prosovetskaya A.L.Medicines for the treatment of STDs.

New pharmacy. 2006;7:28–31.

Sergeev A.Yu., Sergeev Yu.V. Candidiasis: naturalyes infections, mechanisms of aggression and defense, diagnosis and treatment. M., 2000.

Malova I.O., Rakhmatulina M.R., Sokolov-E.V.skiy Federal clinical recommendations guidelines for the management of patients with urogenital diseases candidiasis (National clinical guidelines).

Evidence-based medicine. Annual Vochnik. Part 4 / Ed. S.E. Baschinsky. M.,2003. pp. 1341–54.

Clinical pharmacology according to Goodman and Gilman / Under the general editorship. A.G. Gilman, editors J. Hardman and L. Limbird. Per. With English M., 2006. P. 1001–8.

Reef S.E., Levine W.C., McNeil M.M., Fisher-Hoch S., Holmberg S.D., Duerr A., Smith D.,Sobel J.D., Pinner R.W. Treatment options for vulvovaginal candidiasis, 1993. Clin. Infect. Dis.1995;20(Suppl. 1):S80.

Belikova Z.F. Complex therapy pia of urogenital candidiasis in women -women of reproductive age, taking into account vaginal and intestinal conditions microbiocenosis: Diss. Ph.D. honey. Sci.M., 2000.